0000-0003-3949-5744 About
My long-term research interest is to identify promising cancer therapeutic targets and develop efficacious cancer therapeutic drugs or regimens through understanding the biology, particularly survival and death mechanisms of cancer cells. My earlier research work focused on the molecular identity of cellular calcium homeostasis, tumor differentiation, tumor progression, metastasis, multi-drug resistance, blood pressure regulation and intervention strategies. During postdoc work, my research has focused on overcoming acquired resistance to 3rd generation EGFR inhibitors (e.g., osimertinib) in non-small cell lung cancer. Several of my current and previous projects are briefly described below.
Employment
-
Emory University Assistant Professor2024 - Present
-
Emory University Postdoc Fellow2018 - 2024
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (10)
- Inhibition of PGC1β-dependent mitochondrial biogenesis enhances EGFR-targeted therapy in lung cancer Save
- Targeting MKK3/c-Myc interaction to overcome osimertinib acquired resistance in EGFR mutant lung cancer Save
- Induction of IL6/STAT3-dependent TRAIL expression that contributes to the therapeutic efficacy of osimertinib in EGFR mutant NSCLC cells Save
- Inhibition of hTERT/telomerase/telomere mediates therapeutic efficacy of osimertinib in EGFR mutant lung cancer Save
- Targeting Transient Receptor Potential Melastatin‐2 (TRPM2) Enhances Therapeutic Efficacy of Third Generation EGFR Inhibitors against EGFR Mutant Lung Cancer Save
- DNA topoisomerase II inhibition potentiates osimertinib's therapeutic efficacy in EGFR-mutant non-small cell lung cancer models. Save
- The natural product berberine synergizes with osimertinib preferentially against MET-amplified osimertinib-resistant lung cancer via direct MET inhibition Save
- Induction of SREBP1 degradation coupled with suppression of SREBP1-mediated lipogenesis impacts the response of EGFR mutant NSCLC cells to osimertinib Save
- Targeting c-Myc to Overcome Acquired Resistance of EGFR Mutant NSCLC Cells to the Third-Generation EGFR Tyrosine Kinase Inhibitor, Osimertinib Save
- Downregulation of death receptor 4 is tightly associated with positive response of EGFR mutant lung cancer to EGFR-targeted therapy and improved prognosis. Save